About us
Who we are
Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. Our member companies are at the forefront of the global development and marketing of biosimilar medicines.
Biosimilars Canada provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocates for policies that support their timely approval, reimbursement, market acceptance and expanded use. Maximizing the use of biosimilar medicines provides a significant contribution to the sustainability of drug plans and healthcare systems while supporting positive patient outcomes.
In collaboration with its partners in the International Generic and Biosimilar Medicines Association (IGBA), Biosimilars Canada seeks to address global developments for the biosimilar medicines industry and participates in initiatives to raise the domestic and global awareness of biosimilar medicines such as Global Biosimilars Week. Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association.
Biosimilars Canada Board
Mike Casia, Organon – Chair
Mike Woolcock, Apobiologix – Vice Chair
Kamlesh Thakkar, Auropharma Inc.
Rosemarie (Rosie) Childerhose, Biocon Biologics
Martin Willner, Fresenius Kabi
Mike Dutton, Pharmascience
Michel Robidoux, Sandoz
Barb Pimentel, Taro
Ben Gray, Teva
Fabien Paquette, Teva
Jim Keon, Biosimilars Canada (Ex-Officio)
Member companies
